Assessment of the effectiveness of vonoprazan C-CBK in the complex of eradication therapy in patients with chronic Hp-associated gastritis
https://doi.org/10.31146/1682-8658-ecg-220-12-54-58
Abstract
The article presents data on the results of a comparative study of the clinical and antihelicobacteric efficacy of two schemes of eradication therapy in 60 patients with HP-associated chronic gastritis. The main group of patients received eradication therapy consisting of vonoprazane, amoxicillin, clarithromycin and bismuth tricalium decitrate for 10 days. In the second group of patients with chronic gastritis, esomeprazole was used as an antisecretory drug against the background of similar therapy. The results of the study showed that in the first group of patients, the dynamics of acid suppression under the influence of vonoprasane was significantly higher compared to esomeprazole. Also, in the main group of patients, the rate of eradication of HP infection was 93%, whereas in the group of patients taking esomeprazole, this indicator was 80%.
About the Authors
M. M. Karimov
Republican Specialized Scientific and Practical Medical Center for Therapy and Medical Rehabilitation
Russian Federation
Russian Federation
M. T. Rustamova
Tashkent Medical Academy
Russian Federation
Russian Federation
G. N. Sobirova
Tashkent Medical Academy
Russian Federation
Russian Federation
P. S. Zufarov
Tashkent Medical Academy
Russian Federation
Russian Federation
S. S. Khairullaeva
Tashkent Medical Academy
Russian Federation
Russian Federation
References
1. Malfertheiner P., Megraud F., O’Morain C., Bazzoli F., El-Omar E., Graham D., Hunt R., Rokkas T., Vakil N., Kuipers E. J. Current concepts in the management of Helicobacter pylori infection: the Maastricht III Consensus Report. Gut. 2007 Jun;56(6):772-81. doi: 10.1136/gut.2006.101634.
2. Malfertheiner P., Megraud F., O’Morain C.A., Gisbert J. P., Kuipers E. J., Axon A. T., Bazzoli F., Gasbarrini A., Atherton J., Graham D. Y., Hunt R., Moayyedi P., Rokkas T., Rugge M., Selgrad M., Suerbaum S., Sugano K., El-Omar E.M.; European Helicobacter and Microbiota Study Group and Consensus panel. Management of Helicobacter pylori infection-the Maastricht V/Florence Consensus Report. Gut. 2017 Jan;66(1):6-30. doi: 10.1136/gutjnl-2016-312288.
3. Sugano K., Tack J., Kuipers E. J., Graham D. Y., El-Omar E.M., Miura S., Haruma K., Asaka M., Uemura N., Malfertheiner P.; faculty members of Kyoto Global Consensus Conference. Kyoto global consensus report on Helicobacter pylori gastritis. Gut. 2015 Sep;64(9):1353-67. doi: 10.1136/gutjnl-2015-309252.
4. Graham D.Y., Dore M. P. Helicobacter pylori therapy: a paradigm shift. Expert Rev Anti Infect Ther. 2016 Jun;14(6):577-85. doi: 10.1080/14787210.2016.1178065.
5. Karimov M.M., Sobirova G. N., Abdullaeva U. K., Aslonova I. Z., Tulyaganova F. M. Serological Diagnostics Of Atrophy Of The Gastric Mucosa. The American Journal of Medical Sciences and Pharmaceutical Research. 2020;2(12), 118-124. doi: 10.37547/TAJMSPR/Volume02Issue12-19.
6. Malfertheiner P., Megraud F., Rokkas Th. et al. Management of Helicobacter pylori infection: the Maastricht VI/Florence consensus report. Gut. 2022 Aug 8; gutjnl-2022-327745.
7. Iwakiri K., Sakurai Y., Shiino M. et al. A randomized, double-blind study to evaluate the acid-inhibitory effect of vonoprazan (20 mg and 40 mg) in patients with proton-pump inhibitor-resistant erosive esophagitis. Therap Adv Gastroenterol. 2017 Jun;10(6):439-451. doi: 10.1177/1756283X17705329.
8. Mori H., Suzuki H. Role of Acid Suppression in Acid-related Diseases: Proton Pump Inhibitor and Potassium-competitive Acid Blocker. J. Neurogastroenterol Motil. 2019 Jan 31; 25(1):6-14. doi: 10.5056/jnm18139.
9. Akazawa Y., Fukuda D., Fukuda Y. Vonoprazan-based therapy for Helicobacter pylori eradication: experience and clinical evidence. Therap Adv Gastroenterol. 2016; 9(6):845-852. doi: 10.1177/1756283X16668093.
10. Murakami K., Sakurai Y., Shiino M., Funao N., Nishimura A., Asaka M. Vonoprazan, a novel potassium-competitive acid blocker, as a component of first-line and second-line triple therapy for Helicobacter pylori eradication: a phase III, randomised, double-blind study. Gut. 2016; 65(9):1439-1446. doi: 10.1136/gutjnl-2015-311304.
11. Suzuki S., Gotoda T., Kusano C., Iwatsuka K., Moriyama M. The Efficacy and Tolerability of a Triple Therapy Containing a Potassium-Competitive Acid Blocker Compared With a 7-Day PPIBased Low-Dose Clarithromycin Triple Therapy. Am J Gastroenterol. 2016;111(7):949-956. doi: 10.1038/ajg.2016.182.
Review
For citations:
Karimov M.M., Rustamova M.T., Sobirova G.N., Zufarov P.S., Khairullaeva S.S. Assessment of the effectiveness of vonoprazan C-CBK in the complex of eradication therapy in patients with chronic Hp-associated gastritis. Experimental and Clinical Gastroenterology. 2023;(12):54-58. (In Russ.) https://doi.org/10.31146/1682-8658-ecg-220-12-54-58
Views:
128
Email this article 